Why Is Endoscopy Needed Before Bevacizumab for HCC?
At a Glance
Before starting atezolizumab plus bevacizumab for hepatocellular carcinoma, an upper endoscopy is often used to check for fragile esophageal or stomach veins caused by cirrhosis. High-risk varices may need banding or medication, and treatment may wait until healing.
In this answer
3 sections
You may need an upper endoscopy before starting a specific first-line treatment for liver cancer (the combination of atezolizumab and bevacizumab) because of a risk of bleeding [1]. While atezolizumab is an immunotherapy, bevacizumab is a targeted medication that can impair blood vessel repair [2]. Hepatocellular carcinoma (HCC) often occurs alongside liver scarring (cirrhosis), which can cause enlarged, fragile veins in your digestive tract called varices [3].
The upper endoscopy—often recommended within six months before starting this regimen—is a vital safety check. It allows your medical team to find and potentially treat high-risk veins, which helps reduce the chance of severe internal bleeding during your cancer treatment [4][5].
🚨 Warning Signs of Internal Bleeding
Gastrointestinal bleeding can be a life-threatening emergency. Seek immediate emergency medical care (call 911 or go to the nearest emergency room) if you experience:
- Vomiting blood or material that looks like coffee grounds
- Black, tarry, or bloody stools
- Fainting, severe dizziness, or unusual weakness
- Confusion or shortness of breath
The Connection Between Liver Cancer and Fragile Veins
The liver acts as a vital filter for blood. When the liver is scarred from cirrhosis, blood cannot flow through it easily. This resistance causes blood pressure to build up in the major vein that brings blood to the liver—a condition known as portal hypertension [1].
To bypass the blockage, blood finds alternative routes through smaller veins, especially those in the lower esophagus (the swallowing tube) and stomach. Because these small veins are not built to handle high blood pressure, they can stretch and become fragile [3]. These enlarged veins are known as gastroesophageal varices.
Why Bevacizumab Increases Bleeding Risk
Atezolizumab plus bevacizumab is a recommended first-line option for selected patients with advanced HCC [6]. While atezolizumab helps your immune system attack the cancer, bevacizumab works by blocking VEGF, a protein that tumors use to grow new blood vessels [1][2].
However, blocking VEGF also impairs your body’s normal ability to repair blood vessels and heal wounds. Because of this, bevacizumab increases the risk of serious bleeding [1][2]. If an untreated, high-risk varix in your esophagus were to bleed while you were taking bevacizumab, the hemorrhage could be severe and difficult to stop [3].
Screening and Securing the Veins
Because this risk is serious, clinical guidelines and protocols frequently recommend that patients undergo an upper endoscopy (an EGD) before starting a bevacizumab-containing regimen, unless they have had a recent qualifying exam [4][5].
During this brief procedure, a doctor passes a small, flexible camera down your throat while you are sedated to look for varices. The findings dictate what happens next:
- Observation: If no varices or only low-risk varices are found, no immediate treatment may be needed, and you may be cleared to start cancer therapy.
- Variceal Banding (Ligation): If high-risk esophageal varices are found, the doctor can place tiny rubber bands around them to close them off [4]. This helps reduce the risk of bleeding, though it does not eliminate it entirely.
- Medication: Depending on the type and size of the varices, your doctor might prescribe a daily medication (like a nonselective beta-blocker) to lower the blood pressure in your digestive veins [7]. This can be used instead of, or alongside, banding.
If you require banding, you will likely need to wait before starting bevacizumab. Medical teams often wait at least a couple of weeks for the post-banding ulcers to heal completely, and they may require a repeat endoscopy to ensure the varices are fully secured before you receive your first cancer infusion. If bevacizumab is deemed too risky due to varices, your oncology team will discuss alternative effective treatments for your liver cancer.
Note on Medications: Do not stop or restart any prescribed blood thinners or daily aspirin on your own. Always consult with your prescribing doctor and endoscopy team for individualized instructions.
Common questions in this guide
Why is an upper endoscopy recommended before bevacizumab for HCC?
Does everyone with liver cancer need an endoscopy before atezolizumab and bevacizumab?
What happens if the endoscopy finds varices?
How soon can I receive bevacizumab after variceal banding?
What symptoms could mean that I am bleeding from varices?
What if varices make bevacizumab too risky?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Did my recent endoscopy show any esophageal or gastric varices, and if so, how large are they and are they considered high-risk?
- 2.Were my varices treated during the endoscopy, or do I need to take a daily beta-blocker to lower the pressure?
- 3.How long after an endoscopy or a banding procedure do we need to wait for healing before I can safely receive my first bevacizumab infusion?
- 4.Will I need repeat endoscopies while I am on treatment to ensure no new varices develop or to confirm the bands worked?
- 5.If my varices make bevacizumab unsafe, what other effective treatment options can we consider for my liver cancer?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (7)
- 1
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.
Ben Khaled N, Mohr R, Jochheim LS, et al.
JHEP reports : innovation in hepatology 2026; (8(6)):101818 doi:10.1016/j.jhepr.2026.101818.
PMID: 42061924 - 2
Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis.
Song YG, Yeom KM, Jung EA, et al.
Liver cancer 2024; (13(6)):590-600 doi:10.1159/000539423.
PMID: 39687040 - 3
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab.
Hsu C, Rimassa L, Sun HC, et al.
Therapeutic advances in medical oncology 2021; (13()):17588359211031141 doi:10.1177/17588359211031141.
PMID: 34377156 - 4
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Casak SJ, Donoghue M, Fashoyin-Aje L, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(7)):1836-1841 doi:10.1158/1078-0432.CCR-20-3407.
PMID: 33139264 - 5
Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications.
Lee CL, Freeman M, Burak KW, et al.
Cancers 2024; (16(16)) doi:10.3390/cancers16162878.
PMID: 39199649 - 6
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, et al.
Journal of hepatology 2022; (76(4)):862-873 doi:10.1016/j.jhep.2021.11.030.
PMID: 34902530 - 7
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies.
Li H, Zhou J, Zhu X
Biomedicines 2026; (14(8)) doi:10.3390/biomedicines14081735.
PMID: 42652118
This page is for informational purposes only and does not constitute medical advice. Your oncology and endoscopy teams should guide endoscopy timing, bleeding-risk treatment, and medication decisions for your specific situation.
Get notified when new evidence is published on Adult hepatocellular carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.